Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics

Double, 2010, Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions?, Progress Neurobiol., 92, 316, 10.1016/j.pneurobio.2010.06.001

Barnham, 2008, Metals in Alzheimer's and Parkinson's diseases, Curr. Opin. Chem. Biol., 12, 222, 10.1016/j.cbpa.2008.02.019

Ward, 2012, Chelating agents for neurodegenerative diseases, Curr. Med. Chem., 19, 2760, 10.2174/092986712800609689

Sutachan, 2012, Cellular and molecular mechanisms of antioxidants in Parkinson's disease, Nutr. Neurosci., 15, 120, 10.1179/1476830511Y.0000000033

Bandmann, 2015, Wilson's disease and other neurological copper disorders, Lancet Neurol., 14, 103, 10.1016/S1474-4422(14)70190-5

Zlatic, 2015, Fluphenazine.HCl and epigallocatechin gallate modulate the rate of formation and structural properties of apolipoprotein C-II Amyloid Fibrils, Biochemistry, 54, 3831, 10.1021/acs.biochem.5b00399

Davies, 2013, Localization of copper and copper transporters in the human brain, Metallomics, 5, 43, 10.1039/C2MT20151H

Dexter, 1991, Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia, Brain, 114, 1953, 10.1093/brain/114.4.1953

Bohic, 2008, Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy, Anal. Chem., 80, 9557, 10.1021/ac801817k

Lutsenko, 2008, Cellular multitasking: the dual role of human Cu-ATPases in cofactor delivery and intracellular copper balance, Arch. Biochem. Biophys., 476, 22, 10.1016/j.abb.2008.05.005

Brewer, 2008, The risks of free copper in the body and the development of useful anticopper drugs, Curr. Opin. Clin. Nutr. Metab. Care, 11, 727, 10.1097/MCO.0b013e328314b678

Bauerly, 2004, Functional and molecular responses of suckling rat pups and human intestinal Caco-2 cells to copper treatment, J. Nutr. Biochem., 15, 155, 10.1016/j.jnutbio.2003.10.008

Kuo, 2006, Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status, J. Nutr., 136, 21, 10.1093/jn/136.1.21

Nevitt, 2012, Charting the travels of copper in eukaryotes from yeast to mammals, Biochim. Biophys. Acta, 1823, 1580, 10.1016/j.bbamcr.2012.02.011

Ohgami, 2006, The Steap proteins are metalloreductases, Blood, 108, 1388, 10.1182/blood-2006-02-003681

Kelly, 1996, A murine model of Menkes disease reveals a physiological function of metallothionein, Nat. Genet., 13, 219, 10.1038/ng0696-219

Klomp, 1996, Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia, Hum. Mol. Genet., 5, 1989, 10.1093/hmg/5.12.1989

Yoshida, 1995, A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans, Nat. Genet., 9, 267, 10.1038/ng0395-267

Harris, 1995, Aceruloplasminemia: molecular characterization of this disorder of iron metabolism, Proc. Natl. Acad. Sci. U.S.A., 92, 2539, 10.1073/pnas.92.7.2539

Culotta, 1997, The copper chaperone for superoxide dismutase, J. Biol. Chem., 272, 23469, 10.1074/jbc.272.38.23469

Beers, 1997, Purification, characterization, and localization of yeast Cox17p, a mitochondrial copper shuttle, J. Biol. Chem., 272, 33191, 10.1074/jbc.272.52.33191

Cobine, 2006, Mitochondrial matrix copper complex used in metallation of cytochrome oxidase and superoxide dismutase, J. Biol. Chem., 281, 36552, 10.1074/jbc.M606839200

Cobine, 2004, Yeast contain a non-proteinaceous pool of copper in the mitochondrial matrix, J. Biol. Chem., 279, 14447, 10.1074/jbc.M312693200

Maxfield, 2004, Cox17 is functional when tethered to the mitochondrial inner membrane, J. Biol. Chem., 279, 5072, 10.1074/jbc.M311772200

Lee, 2001, Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development, Proc. Natl. Acad. Sci. U.S.A., 98, 6842, 10.1073/pnas.111058698

Takahashi, 2002, Mammalian copper chaperone Cox17p has an essential role in activation of cytochrome C oxidase and embryonic development, Mol. Cell Biol., 22, 7614, 10.1128/MCB.22.21.7614-7621.2002

Oswald, 2009, Knockdown of human COX17 affects assembly and supramolecular organization of cytochrome c oxidase, J. Mol. Biol., 389, 470, 10.1016/j.jmb.2009.04.034

Leary, 2004, Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase, Hum. Mol. Genet., 13, 1839, 10.1093/hmg/ddh197

Rothstein, 1999, The copper chaperone CCS is abundant in neurons and astrocytes in human and rodent brain, J. Neurochem., 72, 422, 10.1046/j.1471-4159.1999.0720422.x

Kim, 2009, Deletion of hepatic Ctr1 reveals its function in copper acquisition and compensatory mechanisms for copper homeostasis, Am. J. Physiol. Gastrointest. Liver Physiol., 296, G356, 10.1152/ajpgi.90632.2008

Lee, 2002, Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system, J. Biol. Chem., 277, 40253, 10.1074/jbc.M208002200

Ip, 2010, Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue, Mol. Pain, 6, 53, 10.1186/1744-8069-6-53

Mercer, 1993, Isolation of a partial candidate gene for Menkes disease by positional cloning, Nat. Genet., 3, 20, 10.1038/ng0193-20

Gouider-Khouja, 2009, Wilson's disease, Parkinsonism Relat. Disord., 15, S126, 10.1016/S1353-8020(09)70798-9

Capo, 2008, Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients, Biometals, 21, 367, 10.1007/s10534-007-9125-4

Holtzman, 1970, Studies on the rate of release and turnover of ceruloplasmin and apoceruloplasmin in rat plasma, J. Biol. Chem., 245, 2354, 10.1016/S0021-9258(18)63159-X

Gaetke, 2003, Copper toxicity, oxidative stress, and antioxidant nutrients, Toxicology, 189, 147, 10.1016/S0300-483X(03)00159-8

Valko, 2005, Metals, toxicity and oxidative stress, Curr. Med. Chem., 12, 1161, 10.2174/0929867053764635

Litwin, 2013, Brain metal accumulation in Wilson's disease, J. Neurol. Sci., 329, 55, 10.1016/j.jns.2013.03.021

Gray, 2012, Urinary copper elevation in a mouse model of Wilson's disease is a regulated process to specifically decrease the hepatic copper load, PloS One, 7, e38327, 10.1371/journal.pone.0038327

Kim, 2010, Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition and storage organs, Cell Metab., 11, 353, 10.1016/j.cmet.2010.04.003

Campanella, 1973, Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4–4602, amantadine), Acta Neurol., 28, 1

Jimenez-Jimenez, 1992, Serum levels of zinc and copper in patients with Parkinson's disease, J. Neurol. Sci., 112, 30, 10.1016/0022-510X(92)90127-7

Jimenez-Jimenez, 1998, Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease, J. Neural. Transm., 105, 497, 10.1007/s007020050073

Pall, 1987, Raised cerebrospinal-fluid copper concentration in Parkinson's disease, Lancet, 2, 238, 10.1016/S0140-6736(87)90827-0

Torsdottir, 1999, Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease, Pharmacol. Toxicol., 85, 239, 10.1111/j.1600-0773.1999.tb02015.x

Arnal, 2010, Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives, Brain Res., 1319, 118, 10.1016/j.brainres.2009.11.085

Mariani, 2013, Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis, Neurobiol. Aging, 34, 632, 10.1016/j.neurobiolaging.2012.05.015

Gazzaniga, 1992, A case control study of CSF copper, iron and manganese in Parkinson disease, Ital. J. Neurol. Sci., 13, 239, 10.1007/BF02224396

Takahashi, 1994, Trace elements analysis of serum and cerebrospinal fluid with PIXE–effect of age and changes in parkinsonian patients, Nippon Ronen Igakkai Zasshi, 31, 865, 10.3143/geriatrics.31.865

Loeffler, 1994, Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease, Alzheimer Dis. Assoc. Disord., 8, 190, 10.1097/00002093-199408030-00005

Davies, 2014, Copper pathology in vulnerable brain regions in Parkinson's disease, Neurobiol. Aging, 35, 858, 10.1016/j.neurobiolaging.2013.09.034

Dexter, 1989, Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease, J. Neurochem., 52, 1830, 10.1111/j.1471-4159.1989.tb07264.x

Loeffler, 1996, Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders, Brain Res., 738, 265, 10.1016/S0006-8993(96)00782-2

Ayton, 2013, Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease, Ann. Neurol., 73, 554, 10.1002/ana.23817

Popescu, 2009, Iron, copper, and zinc distribution of the cerebellum, Cerebellum, 8, 74, 10.1007/s12311-008-0091-3

Uitti, 1989, Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains, Can. J. Neurol. Sci., 16, 310, 10.1017/S0317167100029140

Ayton, 2012, Ceruloplasmin dysfunction and therapeutic potential for parkinson disease, Ann. Neurol., 73, 554, 10.1002/ana.23817

Wypijewska, 2010, Iron and reactive oxygen species activity in parkinsonian substantia nigra, Parkinsonism Relat. Disord., 16, 329, 10.1016/j.parkreldis.2010.02.007

Zlatic, 2015, Molecular basis of neurodegeneration and neurodevelopmental defects in Menkes disease, Neurobiol. Dis., 81, 154, 10.1016/j.nbd.2014.12.024

Miotto, 2014, Site-specific copper-catalyzed oxidation of alpha-synuclein: tightening the link between metal binding and protein oxidative damage in Parkinson's disease, Inorg. Chem., 53, 4350, 10.1021/ic4031377

Binolfi, 2010, Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alpha-synuclein, Inorg. Chem., 49, 10668, 10.1021/ic1016752

Wright, 2009, Unique copper-induced oligomers mediate alpha-synuclein toxicity, FASEB J., 23, 2384, 10.1096/fj.09-130039

Santner, 2010, Metalloproteomics and metal toxicology of alpha-synuclein, Metallomics, 2, 378, 10.1039/b926659c

Rose, 2011, Mechanism of copper(II)-induced misfolding of Parkinson's disease protein, Sci. Rep., 1, 11, 10.1038/srep00011

Halliday, 2005, Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease, Brain, 128, 2654, 10.1093/brain/awh584

Tavassoly, 2014, Cu(II) and dopamine bind to alpha-synuclein and cause large conformational changes, FEBS J., 281, 2738, 10.1111/febs.12817

Ha, 2014, Dopamine and Cu+/2+ can induce oligomerization of alpha-synuclein in the absence of oxygen: two types of oligomerization mechanisms for alpha-synuclein and related cell toxicity studies, J. Neurosci. Res., 92, 359, 10.1002/jnr.23323

Wang, 2010, Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity, J. Neurochem., 113, 704, 10.1111/j.1471-4159.2010.06638.x

Wilhelm, 2014, Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins, Science, 344, 1023, 10.1126/science.1252884

Moriarty, 2014, A revised picture of the Cu(II)-alpha-synuclein complex: the role of N-terminal acetylation, Biochemistry, 53, 2815, 10.1021/bi5003025

Miotto, 2015, Copper binding to the N-terminally acetylated, naturally occurring form of alpha-synuclein induces local helical folding, J. Am. Chem. Soc., 137, 6444, 10.1021/jacs.5b01911

Lutsenko, 2010, Copper handling machinery of the brain, Metallomics, 2, 596, 10.1039/c0mt00006j

Miller, 1987, Milk and casein-based diets for the study of brain catecholamines in copper-deficient rats, J. Nutr., 117, 1890, 10.1093/jn/117.11.1890

Prohaska, 1975, Copper deficiency in the developing rat brain: evidence for abnormal mitochondria, J. Neurochem., 25, 221, 10.1111/j.1471-4159.1975.tb06956.x

Yajima, 1979, Neuronal degeneration in the brain of the brindled mouse. II. Ultrastructure of neuronal inclusions in the cerebral cortex, Acta Neuropathol., 48, 133, 10.1007/BF00691154

Prohaska, 1982, Effect of dietary or genetic copper deficiency on brain catecholamines, trace metals and enzymes in mice and rats, J. Nutr., 112, 1706, 10.1093/jn/112.9.1706

Rossi, 2001, Increased susceptibility of copper-deficient neuroblastoma cells to oxidative stress-mediated apoptosis, Free Radic. Biol. Med., 30, 1177, 10.1016/S0891-5849(01)00533-0

Lombardo, 2003, Prolonged copper depletion induces expression of antioxidants and triggers apoptosis in SH-SY5Y neuroblastoma cells, Cell. Mol. Life Sci., 60, 1733, 10.1007/s00018-003-3153-1

Valentine, 2005, Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis, Annu. Rev. Biochem., 74, 563, 10.1146/annurev.biochem.72.121801.161647

Girotto, 2014, DJ-1 is a copper chaperone acting on SOD1 activation, J. Biol. Chem., 289, 10887, 10.1074/jbc.M113.535112

Polazzi, 2013, Copper-zinc superoxide dismutase (SOD1) is released by microglial cells and confers neuroprotection against 6-OHDA neurotoxicity, Neuro-Signals, 21, 112, 10.1159/000337115

Torsdottir, 2006, Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study, J. Neurol. Sci., 241, 53, 10.1016/j.jns.2005.10.015

Boll, 2008, Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases, Neurochem. Res., 33, 1717, 10.1007/s11064-008-9610-3

Alcaraz-Zubeldia, 2001, Neuroprotective effect of acute and chronic administration of copper (II) sulfate against MPP+ neurotoxicity in mice, Neurochem. Res., 26, 59, 10.1023/A:1007680616056

Rubio-Osornio, 2009, Copper reduces striatal protein nitration and tyrosine hydroxylase inactivation induced by MPP+ in rats, Neurochem. Int., 54, 447, 10.1016/j.neuint.2009.01.019

Przedborski, 1992, Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity, J. Neurosci., 12, 1658, 10.1523/JNEUROSCI.12-05-01658.1992

Miller, 1991, Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium, J. Neurochem., 57, 541, 10.1111/j.1471-4159.1991.tb03784.x

Furukawa, 2006, Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis, Antioxid. Redox Signal., 8, 847, 10.1089/ars.2006.8.847

Lamb, 2001, Heterodimeric structure of superoxide dismutase in complex with its metallochaperone, Nat. Struct. Biol., 8, 751, 10.1038/nsb0901-751

Schmidt, 1999, Multiple protein domains contribute to the action of the copper chaperone for superoxide dismutase, J. Biol. Chem., 274, 23719, 10.1074/jbc.274.34.23719

Wang, 2011, DJ-1 modulates the expression of Cu/Zn-superoxide dismutase-1 through the Erk1/2-Elk1 pathway in neuroprotection, Ann. Neurol., 70, 591, 10.1002/ana.22514

Bandopadhyay, 2004, The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease, Brain, 127, 420, 10.1093/brain/awh054

McCarthy, 2004, Prana Biotechnology, Limited: metal attenuation in the treatment of neurodegenerative disease, Chem. Biol., 11, 1473, 10.1016/j.chembiol.2004.12.003

Litwin, 2013, Wilson disease–factors affecting clinical presentation, Neurol. Neurochir. Pol., 47, 161, 10.5114/ninp.2013.34397

Lewis, 2001, Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy, Proc. Natl. Acad. Sci. U.S.A., 98, 1206, 10.1073/pnas.98.3.1206

Hung, 2012, The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease, J. Exp. Med., 209, 837, 10.1084/jem.20112285

Bica, 2014, Neuroprotective copper bis(thiosemicarbazonato) complexes promote neurite elongation, PLoS One, 9, e90070, 10.1371/journal.pone.0090070

Ikawa, 2011, Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET, Nucl. Med. Biol., 38, 945, 10.1016/j.nucmedbio.2011.02.016

Ritchie, 2003, Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial, Arch. Neurol., 60, 1685, 10.1001/archneur.60.12.1685

Cahoon, 2009, The curious case of clioquinol, Nat. Med., 15, 356, 10.1038/nm0409-356

Lannfelt, 2008, Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial, Lancet Neurol., 7, 779, 10.1016/S1474-4422(08)70167-4

Faux, 2010, PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses, J. Alzheimers Dis., 20, 509, 10.3233/JAD-2010-1390

Price, 2008, Activation of epidermal growth factor receptor by metal-ligand complexes decreases levels of extracellular amyloid beta peptide, Int. J. Biochem. Cell Biol., 40, 1901, 10.1016/j.biocel.2008.01.033

White, 2006, Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity, J. Biol. Chem., 281, 17670, 10.1074/jbc.M602487200

Crouch, 2011, The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity, J. Neurochem., 119, 220, 10.1111/j.1471-4159.2011.07402.x

Huntington Study Group Reach2HD Investigators, 2015, Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial, Lancet Neurol., 14, 39, 10.1016/S1474-4422(14)70262-5

Wilkins, 2009, Clioquinol protects against cell death in Parkinson's disease models in vivo and in vitro, Basal Ganglia IX, 431, 10.1007/978-1-4419-0340-2

Kaur, 2003, Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease, Neuron, 37, 899, 10.1016/S0896-6273(03)00126-0

Osherovich, 2012, Buddy system for orphan disease, SciBX, 5, 1020

Finkelstein, 2013, PBT434, a novel 8-hydroxyquinazolinone, preserves nigro-striatal circuitry, improves motor performance and inhibits alpha syncuclein accumulation in animal models of Parkinson's disease by modulation of iron homeostasis, Movement Disorders, Abstract Supplement, Abstracts of the 17th International Congress of Parkinson's Disease and Movement Disorders, Sydney, Australia, 16–20 June 2013, 28, S369